一分钟看懂
这是一项关于淋巴瘤的I 期 / II 期研究，登记的药物或干预包括Linperlisib in combination with CHOP，当前状态为研究进行中，已停止招募。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Linperlisib in combination with CHOP · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University · 广州
公开的入选条件
- 1. Histologically confirmed PTCL, including peripheral T-cell lymphoma non-specific type (PTCL NOS), angioimmunoblastic T-cell lymphoma (AITL), enteropathy related T-cell lymphoma and liver spleen T-cell lymphoma;
- 2. Has not received anti-tumor treatment in the past;
- 3. There must be at least one evaluable lesion/measurable lesion according to the 2014 Lugano Lymphoma Evaluation Criteria. An evaluable lesion is defined as a lymph node or extra-nodal local lesion that shows increased uptake of 18FDG on PET-CT (higher than t
- 4. Age ≥18 years old, regardless of gender;
- 5. Whole body physical condition score (ECOG) 0-2;
- 6. Expected survival time\>3 months;
- 7. Adequate bone marrow and organ functions;
- 8. Not accompanied by hemophagocytic syndrome; If the patient is accompanied by clinically diagnosed hemophagocytic syndrome, after targeted anti hemophagocytic syndrome drug treatment, the researcher evaluates the patient's general physical condition to deter
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05949944；登记信息更新于 2026-09-16。